[go: up one dir, main page]

BR9611697A - Polipeptídeo receptor da il-13 - Google Patents

Polipeptídeo receptor da il-13

Info

Publication number
BR9611697A
BR9611697A BR9611697A BR9611697A BR9611697A BR 9611697 A BR9611697 A BR 9611697A BR 9611697 A BR9611697 A BR 9611697A BR 9611697 A BR9611697 A BR 9611697A BR 9611697 A BR9611697 A BR 9611697A
Authority
BR
Brazil
Prior art keywords
receptor polypeptide
polypeptide
receptor
Prior art date
Application number
BR9611697A
Other languages
English (en)
Other versions
BR9611697B1 (pt
Inventor
Daniel Caput
Pascual Ferrara
Natalino Vita
Patrick Laurent
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9485198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9611697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9611697A publication Critical patent/BR9611697A/pt
Publication of BR9611697B1 publication Critical patent/BR9611697B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI9611697-8B1A 1995-12-06 1996-11-07 microrganismo transgÊnico transformado por um vetor de clonagem e/ou de expressço, uso de uma sonda e mÉtodo de diagnàstico in vitro BR9611697B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514424A FR2742156A1 (fr) 1995-12-06 1995-12-06 Polypeptide recepteur de l'il-13
PCT/FR1996/001756 WO1997020926A1 (fr) 1995-12-06 1996-11-07 Polypeptide recepteur de l'il-i3

Publications (2)

Publication Number Publication Date
BR9611697A true BR9611697A (pt) 1999-02-17
BR9611697B1 BR9611697B1 (pt) 2013-09-17

Family

ID=9485198

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9611697-8B1A BR9611697B1 (pt) 1995-12-06 1996-11-07 microrganismo transgÊnico transformado por um vetor de clonagem e/ou de expressço, uso de uma sonda e mÉtodo de diagnàstico in vitro

Country Status (19)

Country Link
US (4) US7928073B2 (pt)
EP (1) EP0876482B1 (pt)
JP (3) JP3415162B2 (pt)
AR (2) AR004860A1 (pt)
AT (1) ATE234922T1 (pt)
AU (1) AU7576096A (pt)
BR (1) BR9611697B1 (pt)
CA (1) CA2238893C (pt)
DE (1) DE69626859T2 (pt)
DK (1) DK0876482T3 (pt)
ES (1) ES2192620T3 (pt)
FR (1) FR2742156A1 (pt)
MX (1) MX9804419A (pt)
MY (1) MY123740A (pt)
NO (3) NO324775B1 (pt)
PT (1) PT876482E (pt)
TW (1) TW565570B (pt)
WO (1) WO1997020926A1 (pt)
ZA (1) ZA9610238B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2238080C (en) * 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
US7078494B1 (en) 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1998010638A1 (en) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6743604B1 (en) 1996-12-13 2004-06-01 Smithkline Beecham Corporation Substances and their uses
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
CA2235420A1 (en) 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
WO2000036103A1 (en) 1998-12-14 2000-06-22 Genetics Institute, Inc. Cytokine receptor chain
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US20020197266A1 (en) * 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2001077332A2 (en) * 2000-04-07 2001-10-18 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
EA011686B1 (ru) 2002-07-15 2009-04-28 Уайт Способ модуляции развития и функций т-клеток-хелперов
ES2385038T3 (es) 2003-12-23 2012-07-17 Genentech, Inc. Nuevos anticuerpos Anti-IL 13 y usos de los mismos
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
MX2007005083A (es) 2004-10-29 2007-10-03 Topigen Pharmaceuticals Inc Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
GB0615881D0 (en) * 2006-08-10 2006-09-20 Univ Southampton Novel peptide for treatment of asthma
CA2685123A1 (en) * 2007-04-23 2008-10-30 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
US9738696B2 (en) 2012-08-09 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
EP2970492B1 (en) 2013-03-15 2019-05-08 Wake Forest University Health Sciences Antibodies against human and canine il-13ra2
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
MY193481A (en) 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−４受容体結合融合タンパク質及びその使用
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6911530B1 (en) * 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain

Also Published As

Publication number Publication date
US20050282216A1 (en) 2005-12-22
US8318910B2 (en) 2012-11-27
PT876482E (pt) 2003-07-31
MX9804419A (es) 1998-09-30
MY123740A (en) 2006-06-30
NO331148B1 (no) 2011-10-24
NO982550L (no) 1998-08-05
BR9611697B1 (pt) 2013-09-17
CA2238893A1 (fr) 1997-06-12
JPH11511028A (ja) 1999-09-28
CA2238893C (fr) 2013-10-08
TW565570B (en) 2003-12-11
JP3737793B2 (ja) 2006-01-25
ZA9610238B (en) 1998-06-05
JP4185070B2 (ja) 2008-11-19
US20060035855A1 (en) 2006-02-16
NO20092994L (no) 1998-08-05
EP0876482B1 (fr) 2003-03-19
DE69626859T2 (de) 2003-12-24
DK0876482T3 (da) 2003-07-21
NO20074034L (no) 1998-08-05
EP0876482A1 (fr) 1998-11-11
US20110201029A1 (en) 2011-08-18
ES2192620T3 (es) 2003-10-16
JP2005323595A (ja) 2005-11-24
AR056723A2 (es) 2007-10-17
NO328197B1 (no) 2010-01-04
DE69626859D1 (de) 2003-04-24
ATE234922T1 (de) 2003-04-15
WO1997020926A1 (fr) 1997-06-12
FR2742156A1 (fr) 1997-06-13
JP3415162B2 (ja) 2003-06-09
US7928073B2 (en) 2011-04-19
AR004860A1 (es) 1999-03-10
AU7576096A (en) 1997-06-27
JP2003180382A (ja) 2003-07-02
NO324775B1 (no) 2007-12-10
US20060035856A1 (en) 2006-02-16
NO982550D0 (no) 1998-06-04

Similar Documents

Publication Publication Date Title
BR9611697A (pt) Polipeptídeo receptor da il-13
NO972016D0 (no) Indolyl-Y-reseptorantagonister
SI0804436T1 (sl) Derivat gvanina
FI973162A0 (fi) Liikalihavuutta vastustavia proteiineja
DE69612316D1 (de) Gelenkige Armlehne
NO976058L (no) Rekombinant mistellectin
DE69512092D1 (de) Gelenkmechanismus
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
FR2733430B1 (fr) Retroverseur pelvien
BR9609671A (pt) Amino uracilas substituídas
FI955400A0 (fi) Tuoli
BR9606756A (pt) Peptídeo
NO981052D0 (no) Peptidderivater
NO981051D0 (no) Peptidderivater
DE59500958D1 (de) Gliederbrücke
DE69615850D1 (de) G-protein-gekoppelter rezeptor hnfd578
KR970007965U (ko) 의자
BR9510060A (pt) Receptor
KR970031728U (ko) 암레스트 고정구조
FI951187L (fi) Istuin
KR970007961U (ko) 의자용 이색판
KR960030269U (ko) 좌의자
GB9511109D0 (en) Receptor proteins
SE9502007D0 (sv) Novel polypeptides
BR1100812A (pt) Peptìdeo

Legal Events

Date Code Title Description
TE Change of address
PC Transfer

Free format text: SANOFI SYNTHELABO (FR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO E CONSIDERADO PATENTEAVEL (ART. 18, INCISO III DA LPI 9279/96), NAO E CONSIDERADO INVENCAO (ART. 10, INCISO IX DA LPI 9279/96), NAO APRESENTA SUFICIENCIA DESCRITIVA (ART. 24 DA LPI 9279/96).

B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: SOLICITO A ANULACAO DO DESPACHO DA DECISAO DE INDEFERIMENTO (RPI 2025) POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS (FR)

Free format text: ALTERADO DE: SANOFI-SYNTHELABO

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.